RCS - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

31/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe8500Ka&default-theme=true

RNS Number : 8500K  Physiomics PLC  31 August 2023

31 August 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company,
supporting development of oncology drugs and personalised medicine solutions,
is pleased to announce that it has been awarded a further contract by existing
client Merck KGaA that it expects to be completed over the next three
months.  The project will involve pre-clinical and clinical modelling and
simulation of anti-cancer regimens involving combinations of DNA damage/
repair agents and follows on from previous projects commissioned by Merck
KGaA.

 

Physiomics CEO, Dr Jim Millen, commented: "We are pleased that this
longstanding client has once again chosen Physiomics as a partner for
outsourced modelling. We look forward to the possibility of further projects
with Merck during the current financial year."

 

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.  Our approach is to derive insight from all
relevant data in order to de-risk decision making and optimise design of
pre-clinical and clinical studies.  Through use of bespoke models and our
proprietary Virtual Tumour technology, the Physiomics team has informed the
development of over 100 projects, over 40 targets and 70 drugs. Clients
include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAWPUUURUPWGAU